Shared on 05 Nov 25
Analysts have modestly increased their price target on CytomX Therapeutics to $6.14 per share, citing ongoing enthusiasm for the CX-2051 program. They also point to reinforced confidence following recent clinical updates and the initiation of coverage.
Shared on 22 Oct 25
Fair value Increased 6.83%Analysts have increased their fair value price target for CytomX Therapeutics from $5.75 to $6.14 per share. This change reflects growing optimism for CX-2051's clinical potential and resilient investor sentiment despite recent safety updates.
Shared on 11 Aug 25
Fair value Increased 14%CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.
Shared on 01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 3.82%AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 62.5x to 72.3x.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 6.07%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget has increased profit margin from 15.8% to 19.6% and decreased future PE multiple from 75.6x to 61.0x.
Shared on 11 Mar 25
Fair value Decreased 11%AnalystConsensusTarget made no meaningful changes to valuation assumptions.